Immune boosters show promise against cancer

2012-06-02 10:01
Chicago - A pair of experimental treatments that fight cancer by boosting the immune system have shown promise in early studies and deserve testing in larger patient groups, said US research released on Saturday.

The drugs, both made by Bristol-Myers Squibb, work by breaking down the shield that protects tumour cells. Rather than try to kill the cancer directly, they allow the immune system to do its work against the invading cells.

In the trials which included just over 500 people, as many as one in four patients with non-small cell lung cancer, melanoma and kidney cancer, who had not responded to standard therapies, saw significant shrinkage of their tumours.

Results of the phase 1 clinical trials were published in the New England Journal of Medicine and released at the American Society of Clinical Oncology meeting in Chicago.

The drugs are known as BMS-936558, which blocks a protein PD-1 on the surface of immune cells; and BMS-936559, which blocks a protein PD-L1 expressed on cancer cells.

Scratched the surface

They are in the same class of treatments as other antibody therapies against cancer including Erbitux, Herceptin, and Rituxan.

"We have just scratched the surface of laboratory and clinical research on these drugs," said lead author of the PD-1 study, Suzanne Topalian, professor of surgery and oncology at Johns Hopkins University.

"Based on the positive response rates to these drugs and longevity of many of these responses, we believe that new clinical trials should move forward."

Among the 296 patients who tested in the PD-1 blocking drug, 18% of non-small cell lung cancer patients saw significant tumour shrinkage, as did 28% of melanoma patients and 27% of kidney cancer patients.

A small number of patients, 5% to 9%, saw their disease remain stable for six months or more, though more study is needed to determine the treatment's impact on survival, the researchers said.

"This level of response in patients with advanced lung cancer, which is typically not responsive to immune-based therapies, was unexpected and notable," said lead researcher on the PD-L1 study Julie Brahmer, associate professor of oncology at Johns Hopkins University.

Toxic effects


Among the 207 patients treated with the anti-PD-L1 therapy, 10% of non-small cell lung cancer patients, 17% of melanoma patients, and 12% of kidney cancer patients showed positive responses.

"The positive results from both drugs give us a good indication that the PD-L1/PD-1 pathway is an important target for cancer therapy," said Topalian.

Early analysis showed that among those who responded to the therapy, those responses were maintained for more than a year in half to two-thirds of patients.

However, the treatments also caused serious toxic effects in 14% of patients, including three deaths from lung inflammation, or pneumonitis.

Other significant side effects were colon inflammation and thyroid abnormalities. Some people reported fatigue, itching and rash.

"A major limitation of the various approaches to turning on an immune response to cancer is that the immune system exerts a major effort to avoid immune over activation, which could harm healthy tissues," said an accompanying editorial by doctor Antoni Ribas in the New England Journal of Medicine.

However, Ribas, a melanoma expert at the University of California Los Angeles, pointed out that the treatments may help extend the duration of tumour suppression and could open new doors in personalised treatment.

The research "predicts that these antibodies unleash a memory immune response to cancer", he wrote, adding the approach "may well have a major effect on cancer treatment".

The study authors said the therapies might be most useful if combined with other anti-cancer agents, including cancer vaccines.
Read more on:    cancer  |  health

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.
NEXT ON NEWS24X

linking and moving

2015-04-22 07:36

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
0 comments
Comments have been closed for this article.

Inside News24

 
/News

Book flights

Compare, Book, Fly

Traffic Alerts
Traffic
There are new stories on the homepage. Click here to see them.
 
English
Afrikaans
isiZulu

Hello 

Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.


Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Settings

Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.




Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.